Measures of lung capacity over the long term (greater than 1 year) · people with myasthenia gravis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Activities of daily living · people with myasthenia gravis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with myasthenia gravis
1 finding from 1 review
Number of unscheduled hospitalizations for episodes of chest infection or acute exacerbation of chronic respiratory failure within 1 year of randomization · people with myasthenia gravis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All adverse events · people with myasthenia gravis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Activities of daily living · people with ALS
1 finding from 1 review
Quality of life (change from baseline) in the medium term · people with ALS
1 finding from 1 review
Number of unscheduled hospitalizations for episodes of chest infection or acute exacerbation of chronic respiratory failure within 1 year of randomization · people with ALS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All adverse events · people with ALS
1 finding from 1 review
Measures of lung capacity over the short term (less than 3 months) Measured by: post‐intervention TLC · children and young males with DMD
1 finding from 1 review
Measures of lung capacity over the medium term (greater than 3 months but less than 1 year) · children and young males with DMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functional impairment · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
2 findings from 1 review
Muscle strength · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Respiratory function: change in FVC% (mean change from baseline to 12 months) · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
1 finding from 1 review
Overall survival · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
BM‐MSC showed no clear difference in overall survival compared with no treatment (low certainty).
1 finding from 1 review
Adverse events, total · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
BM‐MSC showed no clear difference in adverse events, total compared with no treatment (low certainty).
1 finding from 1 review
Serious adverse events · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
BM‐MSC showed no clear difference in serious adverse events compared with no treatment (low certainty).
1 finding from 1 review
Change from baseline in 6MWT (metres) · children and adults with SMA type 3
1 finding from 1 review
Cardiopulmonary exercise capacity · children and adults with SMA type 3
1 finding from 1 review
Functional performance · children and adults with SMA type 3
1 finding from 1 review